Skip to main content

Table 1 Results of the outlet census and anti-malarial audit by country and survey year

From: Do anti-malarials in Africa meet quality standards? The market penetration of non quality-assured artemisinin combination therapy in eight African countries

Country Year Screened (N outlets) Anti-malarial audit completed (N outlets) Anti-malarials audited (N drugs) QAACT audited (N drugs) Non-QAACT audited (N drugs)
West and Central Africa
 Benin 2009 1670 844 5233 859 1629
2011 2891 1237 8987 1396 3925
2014 4332 1806 14,378 2483 6454
 DRC, Kinshasa 2009 2368 766 8437 151 1911
2013 3364 931 12,291 216 6022
2015 1168 1056 16,287 853 7389
 DRC, Katanga 2013 2270 771 6493 854 1975
2015 1052 993 8050 1507 2025
 Nigeria 2009 5456 2113 20,841 1192 4624
2011 7938 1486 13,391 2119 1610
2013 5148 1714 14,358 4799 2058
2015 13,483 3473 33,539 9586 7173
East Africa
 Kenya 2010 13,897 1888 8376 2052 2276
2011 11,383 1854 9544 3669 2153
2014 12,676 2133 9899 3234 3133
 Tanzania 2010 3120 624 5544 416 1415
2011 3702 787 9701 2045 2300
2014 4724 2129 17,307 4905 2314
 Uganda 2010 11,153 2410 14,427 2893 3785
2011 16,207 3138 20,283 5495 4683
2013 7932 3307 19,777 7182 4314
2015 9438 4328 26,640 7380 7238
Southern Africa
 Madagascar 2010 6769 2414 5579 1790 184
2011 10,046 2360 7234 3233 172
2013 10,149 1756 6101 3851 116
2015  13,481  1040  3170 1501 4
 Zambia 2009 3378 435 1783 601 158
2011 5436 781 3355 1036 594
2014 5878 980 5012 1260 1496